446 related articles for article (PubMed ID: 32011323)
1. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
2. Latest developments in the treatment of lipoprotein (a).
Bos S; Yayha R; van Lennep JE
Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic management of hyperlipoproteinemia (a).
Kosmas CE; Sourlas A; Mallarkey G; Silverio D; Ynoa DY; Montan PD; Guzman E; Garcia MJ
Drugs Context; 2019; 8():212609. PubMed ID: 31555339
[TBL] [Abstract][Full Text] [Related]
4. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
5. Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a).
Kosmas CE; Bousvarou MD; Papakonstantinou EJ; Tsamoulis D; Koulopoulos A; Echavarria Uceta R; Guzman E; Rallidis LS
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686428
[TBL] [Abstract][Full Text] [Related]
6. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.
Handhle A; Viljoen A; Wierzbicki AS
Vasc Health Risk Manag; 2021; 17():527-542. PubMed ID: 34526771
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
Tsushima T; Tsushima Y; Sullivan C; Hatipoglu B
Endocr Pract; 2023 Jun; 29(6):491-497. PubMed ID: 36563785
[TBL] [Abstract][Full Text] [Related]
9. Hyperlipoproteinemia(a): clinical significance and treatment options.
Berthold HK; Gouni-Berthold I
Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
[TBL] [Abstract][Full Text] [Related]
10. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia.
Pokrovsky SN; Afanasieva OI; Ezhov MV
Curr Atheroscler Rep; 2020 Sep; 22(11):68. PubMed ID: 32945973
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.
Anagnostis P; Karras S; Lambrinoudaki I; Stevenson JC; Goulis DG
Int J Clin Pract; 2016 Dec; 70(12):967-977. PubMed ID: 28032426
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of and treatment options for increased lipoprotein(a)].
Zsíros N; Paragh G; Harangi M
Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic agents to lower lipoprotein (a) levels.
Kolski B; Tsimikas S
Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
[TBL] [Abstract][Full Text] [Related]
19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
20. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
Vuorio A; Watts GF; Kovanen PT
Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
